Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial

683 patients with aggressive B-non Hodgkin lymphoma in first complete remission
- diffuse large B-cell lymphoma  N=662
- follicular lymphoma grade 3b  N=21

- Randomisation
- Rituximab maintenance  N=338
- Observation  N=345

Event-free survival (primary endpoint)*
- Rituximab maintenance: 80.1%
- Observation: 76.5%
- p=0.0670

Progression-free survival (secondary endpoint)
- Rituximab maintenance: 86.3%
- Observation: 79.0%
- p=0.3646

Overall-free survival (secondary endpoint)
- Rituximab maintenance: 92.0%
- Observation: 90.3%
- p=0.3184

* Male patients benefited from rituximab maintenance regarding event-free survival

Differences were not significant for the intent to treat population

Jaeger et al., Haematologica, 2015